Arvelle Therapeutics Overview
- Founded
-
2019

- Status
-
Acquired/Merged
- Employees
-
60

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$960M
- Investors
-
1
Arvelle Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to deliver innovative treatments to patients suffering from CNS disorders. The company's therapies serve patients suffering from central nervous system disorders for debilitating neurological and neuromuscular diseases and are responsible for the development and commercialization of Cenobamate, enabling clinicians to provide proper medical care for focal seizures of patients.
Contact Information
Website
www.arvelletx.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Parent Company
Angelini Pharma
Primary Office
- Zählerweg 6
- 6301 Zug
- Switzerland
+41 044 000 00 00
Arvelle Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Merger/Acquisition | 02-Feb-2021 | $960M | 00000 | 00000 | Completed | Generating Revenue |
2. Early Stage VC (Series A) | 26-May-2020 | 00000 | 00000 | Completed | Generating Revenue | |
1. Corporate | 01-Feb-2019 | Completed | Startup |
Arvelle Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Operator of a biopharmaceutical company intended to deliver innovative treatments to patients suffering from CNS disorde
Drug Discovery
Zug, Switzerland
60
As of 2021
00000
0000
0000-00-00
000000&0
00000
Arvelle Therapeutics Competitors (36)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Metabolic Solutions Development | Venture Capital-Backed | Kalamazoo, MI | 00 | 0000 | 000000 - 000 | 0000 |
0000000 | Formerly VC-backed | Emeryville, CA | 000 | 00000 | 000000&0 | 00000 |
00000000 | Corporation | Julich, Germany | 0 | 0000000000 | ||
00000 000000000000 | Formerly VC-backed | Burnaby, Canada | 000 | 000.00 | 000000000 | 000.00 |
0000000 | Venture Capital-Backed | Palm Beach Gardens, FL | 00 | 0000 | 000000 - 000 | 0000 |
Arvelle Therapeutics Executive Team (4)
Arvelle Therapeutics Signals
Arvelle Therapeutics Former Investors (8)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Andera Partners | PE/Buyout | Minority | 000 0000 | 000000 0 | |
BRV Capital Management | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
EQT Life Sciences | Venture Capital | Minority | 000 0000 | 000000 0 | |
F-Prime Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
H.I.G. BioHealth Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Arvelle Therapeutics Investments (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000000 00 | 20-Feb-2019 | 000000000 | 00000 | Buildings and Property |